AMENDMENT

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Canceled)

2. (Currently Amended) A eukaryotic cell *in vitro* comprising a vector, said ~~vectorcomprising~~ vector comprising (i) a first promoter operably linked to a nucleotide sequence encoding a selectable marker, wherein said nucleotide sequence lacks a functional polyadenylation signal, and (ii) a second promoter operably linked to an unpaired splice donor, wherein said vector is non-homologously integrated into the genome of said eukaryotic cell in such a way that a fusion transcript comprising the nucleotide sequence encoding the selectable marker ~~and/or~~ or the unpaired splice donor or both and one or more exons of an endogenous gene is expressed under the control of said first or said second promoter and wherein said unpaired splice donor is spliced to a splice acceptor of said endogenous gene to produce said fusion transcript, and coding sequence in said endogenous gene is translated.

3. (Currently Amended) A eukaryotic cell *in vitro* comprising a vector, said vector comprising (i) a first promoter operably linked to a nucleotide sequence encoding a selectable marker, wherein said nucleotide sequence lacks a functional polyadenylation signal, and (ii) a second promoter operably linked to an unpaired splice donor, wherein said vector is non-homologously integrated into the genome of said eukaryotic cell in such a way that a fusion transcript comprising the nucleotide sequence encoding the selectable marker ~~and/or~~ or the unpaired splice donor or both and one or more exons of an endogenous gene is expressed under the control of said first or said second promoter, and coding sequence in said endogenous gene is translated.

4. (Previously Presented) The eukaryotic cell of claim 2 or 3, wherein said cell is an animal cell.

5. (Previously Presented) The eukaryotic cell of claim 4, wherein said animal cell is selected from the group consisting of a mammalian cell, an insect cell, an avian cell, an annelid cell, an amphibian cell, a reptilian cell, and a fish cell.

6. (Previously Presented) The eukaryotic cell of claim 4, wherein said animal cell is a mammalian cell.

7. (Previously Presented) The eukaryotic cell of claim 6, wherein said mammalian cell is a human cell.

8. (Previously Presented) The eukaryotic cell of claim 2 or 3, wherein said cell is a plant cell.

9. (Previously Presented) The eukaryotic cell of claim 2 or 3, wherein said cell is a fungal cell.

10. (Previously Presented) The eukaryotic cell of claim 9, wherein said fungal cell is a yeast cell.

11. (Currently Amended) The eukaryotic cell of claim 4, wherein said cell is ~~an~~ isolated and cloned ~~cell~~.

12-21. (Withdrawn).

22. (Currently Amended) A library of eukaryotic cells *in vitro* comprising a vector, said vector comprising (i) a first promoter operably linked to a nucleotide sequence encoding a selectable marker, wherein said nucleotide sequence lacks a functional polyadenylation signal, and (ii) a second promoter operably linked to an unpaired splice donor, wherein said vector is non-homologously integrated into the genome of said eukaryotic cell in such a way that a fusion transcript comprising the nucleotide sequences encoding the selectable marker ~~and/or~~ or the unpaired splice donor or both and one or more exons of an endogenous gene is expressed under the control of said first or said second promoter and wherein said unpaired splice donor is spliced to a splice acceptor of said endogenous gene to produce said fusion transcript, and coding sequence in said endogenous gene is translated.

23-25. (Withdrawn)

26. (Currently Amended) The ~~vector~~ cell of claim 2 or 3, wherein said ~~promoter is~~ promoters are selected from the group consisting of a CMV immediate early gene promoter, an SV40 T antigen promoter, a tetracycline-inducible promoter, and a β-actin promoter.

27. (Currently Amended) The ~~vector~~ cell of claim 2 or 3, wherein said selectable marker is selected from the group consisting of neomycin, hypoxanthine phosphoribosyl transferase, puromycin, dihydrooratase, glutamine synthetase, histidine D, carbamyl phosphate synthase, dihydrofolate reductase, multidrug resistance 1, aspartate transcarbamylase, xanthine-guanine phosphoribosyl transferase, adenosine deaminase, and thymidine kinase.